Standardisation and consensus guidelines for minimal residual
disease assessment in Philadelphia-positive acute lymphoblastic
leukemia (Ph plus ALL) by real-time quantitative reverse
transcriptase PCR of e1a2 BCR-ABL1

J 2019

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

PFEIFER, H., G. CAZZANIGA, V. H. J VAN DER VELDEN, J. M. CAYUELE, B. SCHAFER et. al.

Basic information

Original name

Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1

Authors

PFEIFER, H. (276 Germany, guarantor), G. CAZZANIGA (380 Italy), V. H. J VAN DER VELDEN (528 Netherlands), J. M. CAYUELE (250 France), B. SCHAFER (756 Switzerland), O. SPINELLI (380 Italy), S. AKIKI (826 United Kingdom of Great Britain and Northern Ireland), S. AVIGAD (376 Israel), I. BENDIT (76 Brazil), K. BORG (616 Poland), H. CAVE (250 France), L. ELIA (380 Italy), S. C. RESHMI (840 United States of America), G. GERRARD (826 United Kingdom of Great Britain and Northern Ireland), S. HAYETTE (250 France), M. HERMANSON (752 Sweden), A. JUH (702 Singapore), Tomáš JURČEK (203 Czech Republic, belonging to the institution), M. C. CHILLON (724 Spain), C. HOMBURG (528 Netherlands), G. MARTINELLI (380 Italy), V. KAIRISTO (246 Finland), T. LANGEN (276 Germany), T. LION (40 Austria), M. C. MUELLER (528 Netherlands), F. PANE (380 Italy), L. RAI (826 United Kingdom of Great Britain and Northern Ireland), C. DAMM-WELK (276 Germany), T. SACHA (616 Poland), S. SCHNITTGER (276 Germany), T. TOULOUMENIDOU (300 Greece), H. VALERHAUGEN (56 Belgium), P. VANDENBERGHE (56 Belgium), J. ZUNA (203 Czech Republic), H. SERVER (276 Germany), E. HERRMANN (276 Germany), S. MARKOVIC (276 Germany), J. J. M VAN DONGEN (528 Netherlands) and O. G. OTTMANN (826 United Kingdom of Great Britain and Northern Ireland)

Edition

Leukemia, London, Nature Publishing Group, 2019, 0887-6924

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

Slovenia

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 8.665

RIV identification code

RIV/00216224:14110/19:00111758

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.1038/s41375-019-0413-0

UT WoS

000479118400006

Keywords in English

STEM-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; FUSION GENE TRANSCRIPTS; BCR-ABL TRANSCRIPTS; HARMONIZING CURRENT METHODOLOGY; TYROSINE KINASE INHIBITORS; ADULT PATIENTS; T-CELL; PERIPHERAL-BLOOD; INTENSITY CHEMOTHERAPY

Abstract

V originále

Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10(-3) and 36/67 (53%) and 53/67 (79%) at 10(-4)BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.

Citovat

PFEIFER, H., G. CAZZANIGA, V. H. J VAN DER VELDEN, J. M. CAYUELE, B. SCHAFER, O. SPINELLI, S. AKIKI, S. AVIGAD, I. BENDIT, K. BORG, H. CAVE, L. ELIA, S. C. RESHMI, G. GERRARD, S. HAYETTE, M. HERMANSON, A. JUH, Tomáš JURČEK, M. C. CHILLON, C. HOMBURG, G. MARTINELLI, V. KAIRISTO, T. LANGEN, T. LION, M. C. MUELLER, F. PANE, L. RAI, C. DAMM-WELK, T. SACHA, S. SCHNITTGER, T. TOULOUMENIDOU, H. VALERHAUGEN, P. VANDENBERGHE, J. ZUNA, H. SERVER, E. HERRMANN, S. MARKOVIC, J. J. M VAN DONGEN and O. G. OTTMANN. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. Leukemia. London: Nature Publishing Group, 2019, vol. 33, No 8, p. 1910-1922. ISSN 0887-6924. Available from: https://dx.doi.org/10.1038/s41375-019-0413-0.

@article{1593316,
   author = {Pfeifer, H. and Cazzaniga, G. and van der Velden, V. H. J and Cayuele, J. M. and Schafer, B. and Spinelli, O. and Akiki, S. and Avigad, S. and Bendit, I. and Borg, K. and Cave, H. and Elia, L. and Reshmi, S. C. and Gerrard, G. and Hayette, S. and Hermanson, M. and Juh, A. and Jurček, Tomáš and Chillon, M. C. and Homburg, C. and Martinelli, G. and Kairisto, V. and Langen, T. and Lion, T. and Mueller, M. C. and Pane, F. and Rai, L. and DammandWelk, C. and Sacha, T. and Schnittger, S. and Touloumenidou, T. and Valerhaugen, H. and Vandenberghe, P. and Zuna, J. and Server, H. and Herrmann, E. and Markovic, S. and van Dongen, J. J. M and Ottmann, O. G.},
   article_location = {London},
   article_number = {8},
   doi = {http://dx.doi.org/10.1038/s41375-019-0413-0},
   keywords = {STEM-CELL TRANSPLANTATION; POLYMERASE-CHAIN-REACTION; FUSION GENE TRANSCRIPTS; BCR-ABL TRANSCRIPTS; HARMONIZING CURRENT METHODOLOGY; TYROSINE KINASE INHIBITORS; ADULT PATIENTS; T-CELL; PERIPHERAL-BLOOD; INTENSITY CHEMOTHERAPY},
   language = {eng},
   issn = {0887-6924},
   journal = {Leukemia},
   title = {Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1},
   url = {http://dx.doi.org/10.1038/s41375-019-0413-0},
   volume = {33},
   year = {2019}
}

TY  - JOUR
ID  - 1593316
AU  - Pfeifer, H. - Cazzaniga, G. - van der Velden, V. H. J - Cayuele, J. M. - Schafer, B. - Spinelli, O. - Akiki, S. - Avigad, S. - Bendit, I. - Borg, K. - Cave, H. - Elia, L. - Reshmi, S. C. - Gerrard, G. - Hayette, S. - Hermanson, M. - Juh, A. - Jurček, Tomáš - Chillon, M. C. - Homburg, C. - Martinelli, G. - Kairisto, V. - Langen, T. - Lion, T. - Mueller, M. C. - Pane, F. - Rai, L. - Damm-Welk, C. - Sacha, T. - Schnittger, S. - Touloumenidou, T. - Valerhaugen, H. - Vandenberghe, P. - Zuna, J. - Server, H. - Herrmann, E. - Markovic, S. - van Dongen, J. J. M - Ottmann, O. G.
PY  - 2019
TI  - Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1
JF  - Leukemia
VL  - 33
IS  - 8
SP  - 1910-1922
EP  - 1910-1922
PB  - Nature Publishing Group
SN  - 08876924
KW  - STEM-CELL TRANSPLANTATION
KW  - POLYMERASE-CHAIN-REACTION
KW  - FUSION GENE TRANSCRIPTS
KW  - BCR-ABL TRANSCRIPTS
KW  - HARMONIZING CURRENT METHODOLOGY
KW  - TYROSINE KINASE INHIBITORS
KW  - ADULT PATIENTS
KW  - T-CELL
KW  - PERIPHERAL-BLOOD
KW  - INTENSITY CHEMOTHERAPY
UR  - http://dx.doi.org/10.1038/s41375-019-0413-0
L2  - http://dx.doi.org/10.1038/s41375-019-0413-0
N2  - Minimal residual disease (MRD) is a powerful prognostic factor in acute lymphoblastic leukemia (ALL) and is used for patient stratification and treatment decisions, but its precise role in Philadelphia chromosome positive ALL is less clear. This uncertainty results largely from methodological differences relating to the use of real-time quantitative PCR (qRT-PCR) to measure BCR-ABL1 transcript levels for MRD analysis. We here describe the first results by the EURO-MRD consortium on standardization of qRT-PCR for the e1a2 BCR-ABL1 transcript in Ph + ALL, designed to overcome the lack of standardisation of laboratory procedures and data interpretation. Standardised use of EAC primer/probe sets and of centrally prepared plasmid standards had the greatest impact on reducing interlaboratory variability. In QC1 the proportion of analyses with BCR-ABL1/ABL1 ratios within half a log difference were 40/67 (60%) and 52/67 (78%) at 10(-3) and 36/67 (53%) and 53/67 (79%) at 10(-4)BCR-ABL1/ABL1. Standardized RNA extraction, cDNA synthesis and cycler platforms did not improve results further, whereas stringent application of technical criteria for assay quality and uniform criteria for data interpretation and reporting were essential. We provide detailed laboratory recommendations for the standardized MRD analysis in routine diagnostic settings and in multicenter clinical trials for Ph + ALL.
ER  -

PFEIFER, H., G. CAZZANIGA, V. H. J VAN DER VELDEN, J. M. CAYUELE, B. SCHAFER, O. SPINELLI, S. AKIKI, S. AVIGAD, I. BENDIT, K. BORG, H. CAVE, L. ELIA, S. C. RESHMI, G. GERRARD, S. HAYETTE, M. HERMANSON, A. JUH, Tomáš JURČEK, M. C. CHILLON, C. HOMBURG, G. MARTINELLI, V. KAIRISTO, T. LANGEN, T. LION, M. C. MUELLER, F. PANE, L. RAI, C. DAMM-WELK, T. SACHA, S. SCHNITTGER, T. TOULOUMENIDOU, H. VALERHAUGEN, P. VANDENBERGHE, J. ZUNA, H. SERVER, E. HERRMANN, S. MARKOVIC, J. J. M VAN DONGEN and O. G. OTTMANN. Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph plus ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1. \textit{Leukemia}. London: Nature Publishing Group, 2019, vol.~33, No~8, p.~1910-1922. ISSN~0887-6924. Available from: https://dx.doi.org/10.1038/s41375-019-0413-0.

Detailed Information on Publication Record